A phase I, single-institution open label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.

Authors

S. R. Ahmed

The Johns Hopkins University School of Medicine, Baltimore, MD

S. R. Ahmed , D. Cosgrove , D. Ball , R. C. Donehower , B. Nelkin , E. Petito , M. Downs , H. X. Chen , A. Doyle , A. Scardina , M. A. Carducci , N. S. Azad

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.

First Author: Shabina Roohi Ahmed

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).

First Author: Maeve Aine Lowery

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.

First Author: Samuel John Harris

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.

First Author: Sarina A. Piha-Paul